Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:NOV-ENPP2 (FusionGDB2 ID:59804)

Fusion Gene Summary for NOV-ENPP2

Fusion gene summary

Fusion gene information	Fusion gene name: NOV-ENPP2
	Fusion gene ID: 59804
		Hgene	Tgene
	Gene symbol	NOV	ENPP2
	Gene ID	6134	5168
	Gene name	ribosomal protein L10	ectonucleotide pyrophosphatase/phosphodiesterase 2
	Synonyms	AUTSX5\|DXS648\|DXS648E\|L10\|MRXS35\|NOV\|QM	ATX\|ATX-X\|AUTOTAXIN\|LysoPLD\|NPP2\|PD-IALPHA\|PDNP2
	Cytomap	Xq28	8q24.12
	Type of gene	protein-coding	protein-coding
	Description	60S ribosomal protein L10Wilms tumor-related proteinlaminin receptor homologlarge ribosomal subunit protein uL16tumor suppressor QM	ectonucleotide pyrophosphatase/phosphodiesterase family member 2E-NPP 2autotaxin-textracellular lysophospholipase Dphosphodiesterase I/nucleotide pyrophosphatase 2plasma lysophospholipase D
	Modification date	20200313	20200313
	UniProtAcc	.	Q13822
	Ensembl transtripts involved in fusion gene	ENST00000259526,	ENST00000075322, ENST00000518109, ENST00000522167, ENST00000522826, ENST00000259486, ENST00000427067,
Fusion gene scores	* DoF score	2 X 2 X 2=8	10 X 9 X 6=540
	# samples	2	11
	** MAII score	log2(2/8*10)=1.32192809488736	log2(11/540*10)=-2.29545588352617 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: NOV [Title/Abstract] AND ENPP2 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	NOV(120431585)-ENPP2(120606100), # samples:5
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	ENPP2	GO:0009395	phospholipid catabolic process	15280042\|26371182
Tgene	ENPP2	GO:0030149	sphingolipid catabolic process	14500380
Tgene	ENPP2	GO:0030334	regulation of cell migration	1733949
Tgene	ENPP2	GO:0034638	phosphatidylcholine catabolic process	21240271
Tgene	ENPP2	GO:0050731	positive regulation of peptidyl-tyrosine phosphorylation	18054784

Fusion gene breakpoints across NOV (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ENPP2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	ESCA	TCGA-JY-A6FD-01A	NOV	chr8	120431585	-	ENPP2	chr8	120606100	-
ChimerDB4	ESCA	TCGA-JY-A6FD-01A	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-
ChimerDB4	ESCA	TCGA-JY-A6FD	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-

Top

Fusion Gene ORF analysis for NOV-ENPP2

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
5CDS-intron	ENST00000259526	ENST00000075322	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-
5CDS-intron	ENST00000259526	ENST00000518109	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-
5CDS-intron	ENST00000259526	ENST00000522167	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-
5CDS-intron	ENST00000259526	ENST00000522826	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-
In-frame	ENST00000259526	ENST00000259486	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-
In-frame	ENST00000259526	ENST00000427067	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000259526

NOV

chr8

120431585

ENST00000259486

ENPP2

chr8

120606100

3059

1004

2623

871

ENST00000259526

NOV

chr8

120431585

ENST00000427067

ENPP2

chr8

120606100

3134

1004

2698

896

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000259526	ENST00000259486	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-	0.001919771	0.99808025
ENST00000259526	ENST00000427067	NOV	chr8	120431585	+	ENPP2	chr8	120606100	-	0.001863173	0.99813676

Top

Fusion Genomic Features for NOV-ENPP2

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

1-p

p (fusion gene breakpoint)

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for NOV-ENPP2

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:120431585/chr8:120606100)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
.	ENPP2 Q13822
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.	FUNCTION: Hydrolyzes lysophospholipids to produce the signaling molecule lysophosphatidic acid (LPA) in extracellular fluids (PubMed:15769751, PubMed:26371182, PubMed:27754931, PubMed:14500380, PubMed:12354767,). Major substrate is lysophosphatidylcholine (PubMed:12176993, PubMed:27754931, PubMed:14500380). Also can act on sphingosylphosphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility (PubMed:14500380). Can hydrolyze, in vitro, bis-pNPP, to some extent pNP-TMP, and barely ATP (PubMed:15769751, PubMed:12176993). Involved in several motility-related processes such as angiogenesis and neurite outgrowth. Acts as an angiogenic factor by stimulating migration of smooth muscle cells and microtubule formation (PubMed:11559573). Stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein (PubMed:1733949). May have a role in induction of parturition (PubMed:12176993). Possible involvement in cell proliferation and adipose tissue development (Probable). Tumor cell motility-stimulating factor (PubMed:1733949, PubMed:11559573). Required for LPA production in activated platelets, cleaves the sn-1 lysophospholipids to generate sn-1 lysophosphatidic acids containing predominantly 18:2 and 20:4 fatty acids (PubMed:21393252). Shows a preference for the sn-1 to the sn-2 isomer of 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) (PubMed:21393252). {ECO:0000269\|PubMed:11559573, ECO:0000269\|PubMed:12176993, ECO:0000269\|PubMed:12354767, ECO:0000269\|PubMed:14500380, ECO:0000269\|PubMed:15769751, ECO:0000269\|PubMed:1733949, ECO:0000269\|PubMed:21240271, ECO:0000269\|PubMed:21393252, ECO:0000269\|PubMed:26371182, ECO:0000269\|PubMed:27754931, ECO:0000305\|PubMed:15700135}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

NOV

chr8:120431585

chr8:120606100

ENST00000259526

108_174

259

358.0

Domain

VWFC

Hgene

NOV

chr8:120431585

chr8:120606100

ENST00000259526

205_250

259

358.0

Domain

TSP type-1

Hgene

NOV

chr8:120431585

chr8:120606100

ENST00000259526

32_105

259

358.0

Domain

IGFBP N-terminal

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000075322

830_851

324

864.0

Region

Required for secretion

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000259486

830_851

376

916.0

Region

Required for secretion

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000522826

830_851

324

889.0

Region

Required for secretion

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

NOV

chr8:120431585

chr8:120606100

ENST00000259526

264_338

259

358.0

Domain

CTCK

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000075322

55_98

324

864.0

Domain

SMB 1

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000075322

99_143

324

864.0

Domain

SMB 2

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000259486

55_98

376

916.0

Domain

SMB 1

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000259486

99_143

376

916.0

Domain

SMB 2

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000522826

55_98

324

889.0

Domain

SMB 1

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000522826

99_143

324

889.0

Domain

SMB 2

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000075322

127_129

324

864.0

Motif

Cell attachment site

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000259486

127_129

376

916.0

Motif

Cell attachment site

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000522826

127_129

324

889.0

Motif

Cell attachment site

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000075322

211_214

324

864.0

Region

Substrate binding

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000075322

244_255

324

864.0

Region

Substrate binding

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000259486

211_214

376

916.0

Region

Substrate binding

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000259486

244_255

376

916.0

Region

Substrate binding

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000522826

211_214

324

889.0

Region

Substrate binding

Tgene

ENPP2

chr8:120431585

chr8:120606100

ENST00000522826

244_255

324

889.0

Region

Substrate binding

Top

Fusion Gene Sequence for NOV-ENPP2

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>59804_59804_1_NOV-ENPP2_NOV_chr8_120431585_ENST00000259526_ENPP2_chr8_120606100_ENST00000259486_length(transcript)=3059nt_BP=1004nt
ACAGCCAATTGCCATGGCAACCCCGGGGTTCGTTCCACTTCCCCACCCAGCCGATCTCCCCCCTCCTCCCTGCACTGCAGCCAACCGGCT
TGTGCGCGTCCCAGGAGCGCGCTATAAAACCTGTGCTGGGCGTGATCGGCAAGCACCGGACCAGGGGGAAGGCGAGCAGTGCCAATCTAC
AGCGAAGAAAGTCTCGTTTGGTAAAAGCGAGAGGGGAAAGCCTGAGCATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGT
GCCTTTGCCTGACCTTCCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCGGGCCGGTGCCCTG
CGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGCTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCT
GCTCAGATCTGGAGCCATGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGCATCTGCACGGCGG
TAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGAGAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAG
ATGGGCAGATTGGCTGTGTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAAGTTGAGGTGCCTG
GAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCACTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCC
TAGGAGTAGAAGTCTCTGACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGTGGTATGGGGTTCT
CCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAGACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGC
AGCCAACAGATAAGATGACAAATCCTCTGAGGGAAATCGACAAAATTGTGGGGCAATTAATGGATGGACTGAAACAACTAAAACTGCATC
GGTGTGTCAACGTCATCTTTGTCGGAGACCATGGAATGGAAGATGTCACATGTGATAGAACTGAGTTCTTGAGTAATTACCTAACTAATG
TGGATGATATTACTTTAGTGCCTGGAACTCTAGGAAGAATTCGATCCAAATTTAGCAACAATGCTAAATATGACCCCAAAGCCATTATTG
CCAATCTCACGTGTAAAAAACCAGATCAGCACTTTAAGCCTTACTTGAAACAGCACCTTCCCAAACGTTTGCACTATGCCAACAACAGAA
GAATTGAGGATATCCATTTATTGGTGGAACGCAGATGGCATGTTGCAAGGAAACCTTTGGATGTTTATAAGAAACCATCAGGAAAATGCT
TTTTCCAGGGAGACCACGGATTTGATAACAAGGTCAACAGCATGCAGACTGTTTTTGTAGGTTATGGCTCAACATTTAAGTACAAGACTA
AAGTGCCTCCATTTGAAAACATTGAACTTTACAATGTTATGTGTGATCTCCTGGGATTGAAGCCAGCTCCTAATAATGGGACCCATGGAA
GTTTGAATCATCTCCTGCGCACTAATACCTTCAGGCCAACCATGCCAGAGGAAGTTACCAGACCCAATTATCCAGGGATTATGTACCTTC
AGTCTGATTTTGACCTGGGCTGCACTTGTGATGATAAGGTAGAGCCAAAGAACAAGTTGGATGAACTCAACAAACGGCTTCATACAAAAG
GGTCTACAGAAGAGAGACACCTCCTCTATGGGCGACCTGCAGTGCTTTATCGGACTAGATATGATATCTTATATCACACTGACTTTGAAA
GTGGTTATAGTGAAATATTCCTAATGCCACTCTGGACATCATATACTGTTTCCAAACAGGCTGAGGTTTCCAGCGTTCCTGACCATCTGA
CCAGTTGCGTCCGGCCTGATGTCCGTGTTTCTCCGAGTTTCAGTCAGAACTGTTTGGCCTACAAAAATGATAAGCAGATGTCCTACGGAT
TCCTCTTTCCTCCTTATCTGAGCTCTTCACCAGAGGCTAAATATGATGCATTCCTTGTAACCAATATGGTTCCAATGTATCCTGCTTTCA
AACGGGTCTGGAATTATTTCCAAAGGGTATTGGTGAAGAAATATGCTTCGGAAAGAAATGGAGTTAACGTGATAAGTGGACCAATCTTCG
ACTATGACTATGATGGCTTACATGACACAGAAGACAAAATAAAACAGTACGTGGAAGGCAGTTCCATTCCTGTTCCAACTCACTACTACA
GCATCATCACCAGCTGTCTGGATTTCACTCAGCCTGCCGACAAGTGTGACGGCCCTCTCTCTGTGTCCTCCTTCATCCTGCCTCACCGGC
CTGACAACGAGGAGAGCTGCAATAGCTCAGAGGACGAATCAAAATGGGTAGAAGAACTCATGAAGATGCACACAGCTAGGGTGCGTGACA
TTGAACATCTCACCAGCCTGGACTTCTTCCGAAAGACCAGCCGCAGCTACCCAGAAATCCTGACACTCAAGACATACCTGCATACATATG
AGAGCGAGATTTAACTTTCTGAGCATCTGCAGTACAGTCTTATCAACTGGTTGTATATTTTTATATTGTTTTTGTATTTATTAATTTGAA
ACCAGGACATTAAAAATGTTAGTATTTTAATCCTGTACCAAATCTGACATATTATGCCTGAATGACTCCACTGTTTTTCTCTAATGCTTG
ATTTAGGTAGCCTTGTGTTCTGAGTAGAGCTTGTAATAAATACTGCAGCTTGAGTTTTTAGTGGAAGCTTCTAAATGGTGCTGCAGATTT
GATATTTGCATTGAGGAAATATTAATTTTCCAATGCACAGTTGCCACATTTAGTCCTGTACTGTATGGAAACACTGATTTTGTAAAGTTG

>59804_59804_1_NOV-ENPP2_NOV_chr8_120431585_ENST00000259526_ENPP2_chr8_120606100_ENST00000259486_length(amino acids)=871AA_BP=332
MPWQPRGSFHFPTQPISPLLPALQPTGLCASQERAIKPVLGVIGKHRTRGKASSANLQRRKSRLVKARGESLSMQSVQSTSFCLRKQCLC
LTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDGCSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEG
DNCVFDGVIYRSGEKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDSLGGLTLAAYRPEATLGV
EVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQTRLCMVRPCEQEPEQPTDKMTNPLREIDKIVGQLMDGLKQLKLHRCV
NVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIE
DIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLN
HLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGY
SEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRV
WNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDN

--------------------------------------------------------------
>59804_59804_2_NOV-ENPP2_NOV_chr8_120431585_ENST00000259526_ENPP2_chr8_120606100_ENST00000427067_length(transcript)=3134nt_BP=1004nt
ACAGCCAATTGCCATGGCAACCCCGGGGTTCGTTCCACTTCCCCACCCAGCCGATCTCCCCCCTCCTCCCTGCACTGCAGCCAACCGGCT
TGTGCGCGTCCCAGGAGCGCGCTATAAAACCTGTGCTGGGCGTGATCGGCAAGCACCGGACCAGGGGGAAGGCGAGCAGTGCCAATCTAC
AGCGAAGAAAGTCTCGTTTGGTAAAAGCGAGAGGGGAAAGCCTGAGCATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGT
GCCTTTGCCTGACCTTCCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCGGGCCGGTGCCCTG
CGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGCTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCT
GCTCAGATCTGGAGCCATGCGACGAGAGCAGTGGCCTCTACTGTGATCGCAGCGCGGACCCCAGCAACCAGACTGGCATCTGCACGGCGG
TAGAGGGAGATAACTGTGTGTTCGATGGGGTCATCTACCGCAGTGGAGAGAAATTTCAGCCAAGCTGCAAATTCCAGTGCACCTGCAGAG
ATGGGCAGATTGGCTGTGTGCCCCGCTGTCAGCTGGATGTGCTACTGCCTGAGCCTAACTGCCCAGCTCCAAGAAAAGTTGAGGTGCCTG
GAGAGTGCTGTGAAAAGTGGATCTGTGGCCCAGATGAGGAGGATTCACTGGGAGGCCTTACCCTTGCAGCTTACAGGCCAGAAGCCACCC
TAGGAGTAGAAGTCTCTGACTCAAGTGTCAACTGCATTGAACAGACCACAGAGTGGACAGCATGCTCCAAGAGCTGTGGTATGGGGTTCT
CCACCCGGGTCACCAATAGGAACCGTCAATGTGAGATGCTGAAACAGACTCGGCTCTGCATGGTGCGGCCCTGTGAACAAGAGCCAGAGC
AGCCAACAGATAAGATGACAAATCCTCTGAGGGAAATCGACAAAATTGTGGGGCAATTAATGGATGGACTGAAACAACTAAAACTGCATC
GGTGTGTCAACGTCATCTTTGTCGGAGACCATGGAATGGAAGATGTCACATGTGATAGAACTGAGTTCTTGAGTAATTACCTAACTAATG
TGGATGATATTACTTTAGTGCCTGGAACTCTAGGAAGAATTCGATCCAAATTTAGCAACAATGCTAAATATGACCCCAAAGCCATTATTG
CCAATCTCACGTGTAAAAAACCAGATCAGCACTTTAAGCCTTACTTGAAACAGCACCTTCCCAAACGTTTGCACTATGCCAACAACAGAA
GAATTGAGGATATCCATTTATTGGTGGAACGCAGATGGCATGTTGCAAGGAAACCTTTGGATGTTTATAAGAAACCATCAGGAAAATGCT
TTTTCCAGGGAGACCACGGATTTGATAACAAGGTCAACAGCATGCAGACTGTTTTTGTAGGTTATGGCTCAACATTTAAGTACAAGACTA
AAGTGCCTCCATTTGAAAACATTGAACTTTACAATGTTATGTGTGATCTCCTGGGATTGAAGCCAGCTCCTAATAATGGGACCCATGGAA
GTTTGAATCATCTCCTGCGCACTAATACCTTCAGGCCAACCATGCCAGAGGAAGTTACCAGACCCAATTATCCAGGGATTATGTACCTTC
AGTCTGATTTTGACCTGGGCTGCACTTGTGATGATAAGGTAGAGCCAAAGAACAAGTTGGATGAACTCAACAAACGGCTTCATACAAAAG
GGTCTACAGAAGCTGAAACCAGGAAATTCAGAGGCAGCAGAAATGAAAACAAGGAAAACATTAATGGAAATTTTGAACCTAGAAAAGAGA
GACACCTCCTCTATGGGCGACCTGCAGTGCTTTATCGGACTAGATATGATATCTTATATCACACTGACTTTGAAAGTGGTTATAGTGAAA
TATTCCTAATGCCACTCTGGACATCATATACTGTTTCCAAACAGGCTGAGGTTTCCAGCGTTCCTGACCATCTGACCAGTTGCGTCCGGC
CTGATGTCCGTGTTTCTCCGAGTTTCAGTCAGAACTGTTTGGCCTACAAAAATGATAAGCAGATGTCCTACGGATTCCTCTTTCCTCCTT
ATCTGAGCTCTTCACCAGAGGCTAAATATGATGCATTCCTTGTAACCAATATGGTTCCAATGTATCCTGCTTTCAAACGGGTCTGGAATT
ATTTCCAAAGGGTATTGGTGAAGAAATATGCTTCGGAAAGAAATGGAGTTAACGTGATAAGTGGACCAATCTTCGACTATGACTATGATG
GCTTACATGACACAGAAGACAAAATAAAACAGTACGTGGAAGGCAGTTCCATTCCTGTTCCAACTCACTACTACAGCATCATCACCAGCT
GTCTGGATTTCACTCAGCCTGCCGACAAGTGTGACGGCCCTCTCTCTGTGTCCTCCTTCATCCTGCCTCACCGGCCTGACAACGAGGAGA
GCTGCAATAGCTCAGAGGACGAATCAAAATGGGTAGAAGAACTCATGAAGATGCACACAGCTAGGGTGCGTGACATTGAACATCTCACCA
GCCTGGACTTCTTCCGAAAGACCAGCCGCAGCTACCCAGAAATCCTGACACTCAAGACATACCTGCATACATATGAGAGCGAGATTTAAC
TTTCTGAGCATCTGCAGTACAGTCTTATCAACTGGTTGTATATTTTTATATTGTTTTTGTATTTATTAATTTGAAACCAGGACATTAAAA
ATGTTAGTATTTTAATCCTGTACCAAATCTGACATATTATGCCTGAATGACTCCACTGTTTTTCTCTAATGCTTGATTTAGGTAGCCTTG
TGTTCTGAGTAGAGCTTGTAATAAATACTGCAGCTTGAGTTTTTAGTGGAAGCTTCTAAATGGTGCTGCAGATTTGATATTTGCATTGAG
GAAATATTAATTTTCCAATGCACAGTTGCCACATTTAGTCCTGTACTGTATGGAAACACTGATTTTGTAAAGTTGCCTTTATTTGCTGTT

>59804_59804_2_NOV-ENPP2_NOV_chr8_120431585_ENST00000259526_ENPP2_chr8_120606100_ENST00000427067_length(amino acids)=896AA_BP=332
MPWQPRGSFHFPTQPISPLLPALQPTGLCASQERAIKPVLGVIGKHRTRGKASSANLQRRKSRLVKARGESLSMQSVQSTSFCLRKQCLC
LTFLLLHLLGQVAATQRCPPQCPGRCPATPPTCAPGVRAVLDGCSCCLVCARQRGESCSDLEPCDESSGLYCDRSADPSNQTGICTAVEG
DNCVFDGVIYRSGEKFQPSCKFQCTCRDGQIGCVPRCQLDVLLPEPNCPAPRKVEVPGECCEKWICGPDEEDSLGGLTLAAYRPEATLGV
EVSDSSVNCIEQTTEWTACSKSCGMGFSTRVTNRNRQCEMLKQTRLCMVRPCEQEPEQPTDKMTNPLREIDKIVGQLMDGLKQLKLHRCV
NVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIE
DIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLN
HLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEAETRKFRGSRNENKENINGNFEPRKERHL
LYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLS
SSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLD

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for NOV-ENPP2

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for NOV-ENPP2

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for NOV-ENPP2

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source